So Does This Drug Work or Not?

When Vertex Pharmaceuticals (Nasdaq: VRTX  ) said back in October that the low dose of VX-222 combined with telaprevir was being stopped because of viral breakthrough, I told subscribers of Motley Fool Rule Breakers not to worry. "All drugs fail to work at some suboptimal dose," I wrote.

Now I'm a little worried.

The higher dose of VX-222 combined with telaprevir also failed to rid patients of their hepatitis C. Like the lower dose, this arm of the study was discontinued because of viral breakthrough -- the drug lowers the viral count, but then the virus finds a way around the drug and starts multiplying again.

Vertex is still testing the drug as part of a four-drug combination with telaprevir and Roche's Pegasys and Copegus at two different doses of VX-222. But the four-drug regimen isn't nearly as convenient as a two-drug regimen, especially given the annoying side effects of Pegasys and the fact that it has to be injected.

Now that the next-generation oral hepatitis C drugs -- telaprevir and Merck's (NYSE: MRK  ) boceprevir -- are on their way to the market, companies want to develop all-oral treatment regimens to avoid Pegasys and its counterpart, PegIntron, which is sold by Merck.

Gilead Sciences (Nasdaq: GILD  ) has seven oral hepatitis C drugs in development. Roche is developing oral drugs as well; it recently took danoprevir off InterMune's (Nasdaq: ITMN  ) hands. The easiest way for Vertex to ensure that telaprevir is part of the all-oral treatment regimen is to develop a combination itself.

Vertex is also testing VX-222 in combination with telaprevir and Copegus. The three-drug all-oral combination would avoid Pegasys, but it's unclear whether adding Copegus will be enough to push the efficacy high enough. If it does work, Copegus is available as a generic, so Vertex could theoretically design a combined pill that contained all three drugs.

We'll know soon enough whether VX-222 has any antiviral activity. Interim data from both of the four-drug treatment arms are expected in the first quarter of next year. Investors will just have to be a little worried until then.

Want to read more about Vertex? Add it to My Watchlist, which will find all of our Foolish analysis on this stock.

Vertex Pharmaceuticals is a Motley Fool Rule Breakers recommendation. Gain access to our members-only discussion boars with a free 30-day trial subscription.

Gilead Sciences is a Motley Fool Stock Advisor choice. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1409895, ~/Articles/ArticleHandler.aspx, 9/17/2014 7:57:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement